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Although it is not common, very high triglyceride (TG) levels 
(>885 mg/dL) may cause clinical complications, and effective 
therapeutic approaches for this metabolic disorder are under 
investigation.1 Although previous studies have described ge-
netic information of patients with very high TG, data from Asian 
countries are highly limited.2-4 Particularly, the prevalence and 
characteristics of patients in Korea have not been analyzed be-
fore. The aim of this study was to investigate the prevalence 
and characteristics of variants of five lipolysis-related genes in 
Korean patients with very high TG. We selected 26 patients 
meeting the lipid criteria from 13545 people and performed 
targeted next generation sequencing of LPL, APOC2, GPIH-
BP1, APOA5, and LMF1 to identify rare and common variants. 
Unrelated patients with very high TG levels were included 
in this study. Between November 2000 and March 2011, 13545 
subjects were enrolled in the Cardiovascular Genome Center 
Cohort, Yonsei University College of Medicine, Seoul, Korea. 
Men and women were recruited in the cohort when they vis-
ited Severance Hospital, Seoul, Korea for cardiovascular dis-
eases or health check-ups. Patients were interviewed about 
their medical histories, and then underwent physical exami-
nations. Among them, 26 subjects with fasting TG >885 mg/dL, 
documented at least two times, were finally included in this 
study. Patients with obesity (body mass index >30 kg/m2), un-
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We investigated the prevalence and characteristics of variants of five lipolysis-related genes in Korean patients with very high tri-
glycerides (TGs). Twenty-six patients with TG levels >885 mg/dL were selected from 13545 Korean subjects. Five candidate genes, 
LPL, APOC2, GPIHBP1, APOA5, and LMF1, were sequenced by targeted next-generation sequencing. Predictions of functional ef-
fects were performed and matched against public databases of variants. Ten rare variants of three genes were found in nine (34.6%) 
patients (three in LPL, four in APOA5, and three in LMF1). Five were novel and all variants were suspected of being disease-caus-
ing. Nine were heterozygous, and one (3.8%) had a homozygous rare variant of LPL. Six common variants of four genes were ob-
served in 25 (96.2%) patients (one in LPL, one in GPIHBP1, two in APOA5, and two in LMF1). The c.G41T variant of GPIHBP1 and 
c.G533T variant of APOA5 were most frequent and found in 15 (57.7%) and 14 (53.8%) patients, respectively. Rare homozygous 
variants of the genes were very uncommon, while diverse rare heterozygous variants were commonly identified. Taken together, 
most study subjects may be manifesting the combined effects of rare heterozygous variants and common variants.
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controlled diabetes mellitus (HbA1c ≥8%), excessive alcohol 
consumption (>15 drinks/week for men or >8 drinks/week for 
women), hypothyroidism, proteinuria, pregnancy, or cortico-
steroids or oral estrogen were excluded. All participants gave 
their written informed consent and Institutional Review Board 
of Severance Hospital approved the study (4-2001-0039).
Five target genes were sequenced: LPL (MIM 609708), 
APOC2 (MIM 608083), GPIHBP1 (MIM 612757), APOA5 (MIM 
606368), and LMF1 (MIM 611761). Genomic DNA from blood 
was extracted with the Qiagen DNeasy kit (Qiagen, Valencia, 
CA, USA). For mutation analysis, a panel for targeted DNA cap-
ture and sequencing by selecting five genes associated with li-
polysis was developed by Celemics, Inc. (Seoul, Korea). For 
targeted sequencing, DNA fragments containing all coding ex-
ons and exon-intron junctions were enriched by solution-based 
hybridization capture, followed by sequencing with an Illumina 
Hiseq2000 platform (Illumina, San Diego, CA, USA). Analysis 
of next-generation sequencing data was performed using an 
in-house analysis pipeline. Variants were called using the GATK 
v3.3.0 Unified Genotyper algorithm (Broad Institute, Cam-
bridge, MA, USA) for loci with sequencing depth greater than 
or equal to 20X. Functional annotation of genetic variants was 
performed by ANNOVAR (ver. 2014-11-12). 
Functional effect predictions for single nucleotide variants 
were performed using SIFT, PolyPhen-2, and MutationTaster, 
and were matched against Korean population exome data 
(n=476) and public databases of variants (dbSNP 138, Exome 
Variant Server and 1000 Genome project SNP from both Asian 
and all-population databases). Analyses comprise evolution-
ary conservation, splice-site changes, loss of protein features, 
and changes that might affect the amount of mRNA. Test re-
sults are then evaluated by a naïve Bayes classifier, which pre-
dicts disease potential. We then prioritized variants according 
to the following criteria: 1) variants that were reported to be 
disease-causing in the Human Gene Mutation Database; 2) 
disruptive variants (nonsense, splice-site, and frameshift) that 
were novel or rare (minor allele frequency <1% in public data-
bases); and 3) novel or rare missense variants that were pre-
dicted to be deleterious by SIFT, Polyphen-2 (HumVar), or Mu-
tationTaster. Variants that met these criteria were validated by 
bidirectional Sanger sequencing of PCR amplicons. 
Clinical characteristics of the study patients are described 
in Table 1. They were younger than the total population, and 
more likely to be male (85%). Among 26 subjects, five (19%) 
had a history of coronary artery disease, whereas one (4%) had 
a history of pancreatitis. The median TG level was 1213 mg/dL, 
while the mean high-density lipoprotein-cholesterol was 32.9 
mg/dL. 
Ten rare variants of three candidate genes were found in 
nine (34.6%) patients (three in LPL, four in APOA5, and three in 
LMF1) (Tables 2 and 3). Six were novel and all variants were 
suspected of being disease-causing. Nine of them were hetero-
zygous, and one (3.8%) subject had homozygous form of a rare 
variant in LPL. Six common variants of four genes were ob-
served in 25 (96.2%) patients (one in LPL, one in GPIHBP1, 
two in APOA5, and two in LMF1) and have been previously re-
ported. Among common variants, c.G41T (p.C14F) of GPIH-
BP1 and c.G533T (p.G185C) of APOA5 were most frequent, and 
were found in 15 (57.7%) and 14 (53.8%) patients, respectively. 
One (3.8%) patient did not show any rare or common variant. 
In addition, no variant was found in APOC2 (Fig. 1).
Three rare variants of LPL, c.G872A (p.C291Y), c.T913C (p.
C305R), and c.T985G (p.Y329D), were identified in three sub-
jects. The c.G872A and c.T985C variants were novel and were 
predicted to be damaging by in silico analysis, while c.T913C 
variant has been known to be associated with LPL deficiency.5 
Only the c.T985G variant was homozygous. One common vari-
ant that has been reported as a stopgain single nucleotide vari-
ant,6 c.C1421G (p.S474X), was found in two patients.
One common variant of GPIHBP1, c.G41T (p.C14F), was 
found in 15 patients and seven of them were homozygous. This 
variant has been reported previously, but its influence on pro-
Table 1. Clinical Characteristics of Study Patients
Total population (n=13545) Patients with very high TG (n=26) p value
Age (yr )   60.4±10.6 46.8±8.6 <0.001
Male 6722 (50)    22 (85) <0.001
Medical history
Hypertension 7234 (53)    11 (42) 0.25
Diabetes mellitus 2293 (17)      5 (19) 0.77
Smoking 2004 (15)    11 (42) 0.01
Coronary artery disease 4747 (35)      5 (19) 0.04
Body mass index (kg/m2) 24.8±3.1 26.7±4.4 0.04
Laboratory values (mg/dL)
Total cholesterol 189±43 282±54 <0.001
TG   117 (83) 1213 (459) <0.001
HDL-C   48.8±14.7   32.9±11.1 <0.001
TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol; SD, standard deviation; IQR, interquartile range. 
Values are presented as mean±SD, n (%), or median (IQR).
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tein function has been only partially shown.7,8 In silico algo-
rithms indicated that this variant could be benign.
Four rare variants of APOA5, c.46delT (p.S16Q fs X40), 
c.C551G (p.T184S), c.C552celC (p.T184T fs X15), and 
c.586_587insC (p.E196fs), were discovered in four subjects. 
Patients possessing these variants were all heterozygous, and 
three of four variants have not been reported before. The 
c.46delT and c.552delC were frameshift deletions; c.586_587insC 
was a frameshift insertion; and c.C551G was a single nucleo-
tide variant. These four rare variants were assumed to be dis-
ease-causing in prediction algorithms. Two common variants 
of APOA5, c.G457A (p.V153M) and c.G553T (p.G185C), were 
found in six and 14 people, respectively. These two variants 
have been previously reported. c.G553T has been known to 
be associated with hypertriglyceridemia,3,9 while c.G457A has 
been reported to be benign.10
Three rare variants of LMF1, c.A1036G (p.M346V), c.G1228A 
(p.G410R), and c.G1621A (p.G541R), were identified in three 
patients. They were all heterozygous and already have been 
reported. In silico analysis indicated that these three variants 
may be disease-causing. Two common variants, c.G107A (p.
G36D) and c.C1685G (p.P562R), were discovered in two and 
nine individuals, respectively. Both of these single nucleotide 
variants were suspected of being benign in prediction algo-
rithms.
The major findings of our study are: 1) 10 rare variants of 
three genes were found in nine (34.6%) patients (three in LPL, 
four in APOA5, and three in LMF1). Among them, five were 
novel and nine were heterozygous. All rare variants were sus-
pected of being disease-causing by in silico analysis. 2) Only 
Table 3. Genetic Variants of Target Genes Identified in Each Individual 
Patients Sex Age TC TG HDL-C
Genes and variants: [nucleotide change], amino acid change
LPL GPIHBP1 APOA5 LMF1
  1 M 32 257   948 45 [c.C1421G], p.S474X [c.G553T], p.G185C [c.C1685G], p.P562R
  2 M 31 366 1305 24 [c.G553T], p.G185C [c.C1685G], p.P562R
  3 M 40 240   992 30 [c.G41T], p.C14F* [c.C1685G], p.P562R
  4 M 34 348 1590 77 [c.C1421G], p.S474X [c.G41T], p.C14F* [c.G553T], p.G185C [c.C1685G], p.P562R
  5 F 57 278 1163 36 [c.G41T], p.C14F [c.G107A], p.G36D
  6 F 52 209 1001 28 [c.G41T], p.C14F [c.G553T], p.G185C
  7 F 58 327 1659 29 [c.G41T], p.C14F*
[c.C551G], p.T184S
[c.G553T], p.G185C
[c.A1036G], p.M346V
  8 M 52 280 1040 34 [c.G41T], p.C14F [c.G1621A], p.G541R
  9 M 42 226 1020 39
[c.46delT], p.S16Q fs X40†
[c.G553T], p.G185C
10 M 38 209   943 37
11 M 47 224 2080 31 [c.G457A], p.V153M
12 M 56 271 1280 33 [c.G41T], p.C14F [c.G553T], p.G185C [c.C1685G], p.P562R
13 M 39 184 1022 32 [c.G553T], p.G185C
14 M 42 253 1370 28 [c.G41T], p.C14F
15 M 48 292 1230 20 [c.G41T], p.C14F
[c.552delC], p.T184T fs X15†
[c.G553T], p.G185C*
16 M 61 326 1489 22 [c.586_587insC], p.E196A fs X71† [c.G107A], p.G36D
17 M 38 323 1196 31 [c.G41T], p.C14F*
[c.G553T], p.G185C
[c.G457A], p.V153M
18 M 40 257 1104 32 [c.G553T], p.G185C*
19 F 56 305 1089 28 [c.G41T], p.C14F*
20 M 51 243   926 44 [c.G457A], p.V153M [c.G1228A], p.G410R
21 M 45 340 1250 34 [c.G41T], p.C14F* [c.C1685G], p.P562R
22 M 51 302 1902 37 [c.G553T], p.G185C*
23 M 53 257 1440 33 [c.G41T], p.C14F* [c.G457A], p.V153M [c.C1685G], p.P562R
24 M 54 258   910 29 [c.G872A], p.C291Y† [c.G41T], p.C14F [c.G553T], p.G185C* [c.C1685G], p.P562R
25 M 52 363 3348 19 [c.T985G], p.Y329D*,† [c.G41T], p.C14F [c.G457A], p.V153M
26 M 55 313 1479 23 [c.T913C], p.C305R
[c.G457A], p.V153M
[c.G553T], p.G185C
[c.C1685G], p.P562R
TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein-cholesterol. 
Rare variants in bold character. 
*Homozygous, †Novel variants. 
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one (3.8%) subject had the homozygous form of a rare variant 
of LPL. 3) Six common variants of four genes were identified 
in 25 (96.2%) patients (one in LPL, one in GPIHBP1, two in APOA5, 
and two in LMF1). 4) c.G41T of GPIHBP1 and c.G553T of 
APOA5 were the most frequent common variants, found in 15 
(57.7%) and 14 (53.8%) patients, respectively. We showed, for 
the first time, the prevalence and characteristics of rare and 
common variants of five lipolysis-related genes in Koreans 
with very high TG. 
To date, more than a hundred homozygous or compound 
heterozygous mutations have been identified and shown to 
cause LPL deficiency. Additional heterozygous mutations have 
also been found to reduce LPL activity.2,11 In our results, one 
rare variant (3.8%), c.T985C, was homozygous, and two rare 
variants (7.7%), c.G872A and c.T913C, were heterozygous. 
Analyses by multiple algorithms predicted that these variants 
may be disease-causing. In patients with severe hypertriglyc-
eridemia of other ethnicities, homozygous or compound het-
erozygous rare variants of LPL were in 1% in Thai study,4 20% 
in Dutch study,12 and 23% in Italian study.13 Conversely, het-
erozygous rare variants were 6% in Canadian and Dutch stud-
ies,12,14 10% in Italian study,13 and 11% in Thai study.4 The preva-
lence of such variants in our study was lower than in those 
studies; nonetheless, homozygous variants appear scarce in 
Asian studies, including ours. It is worth mentioning that loci 
of rare variants of LPL are quite diverse. Only one common 
variant of LPL, c.C1421G, was discovered in two of our sub-
jects. However, it is uncertain whether this variant is associat-
ed with hypertriglyceridemia, because these patients had oth-
er common functional variants, such as c.G553T. In addition, 
the relationship between the variant and phenotype was not 
consistent in prior studies.4,15
Although rare variants of GPIHBP1 are steadily being dis-
covered,12,16 only one form of the common variant was identi-
fied in our study. The biological impact of our variant, c.G41T, 
is only partially known. This variant was identified in 11% of 
French patients with severe hypertriglyceridemia, in associa-
80
60
40
20
0
Ca
rri
er
s (
%
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LPL APOC2 GPIHBP1 APOA5 LMF1
  Rare, homozygous
  Rare, heterozygous
  Common, homozygous
  Common, heterozygous
Fig. 1. Proportion of carriers who have variants of each gene identified 
in the study population.
tion with a mutation in another site of GPIHBP1. In that study, 
the c.G41T variant was shown to be associated with mildly re-
duced protein levels, and was assumed to influence pheno-
type.7 This variant was also identified in 26% of Spanish pa-
tients with the same lipid trait. However, most patients with 
this variant simultaneously had other variants related to TG 
levels, thus the impact of this variant was not sufficiently clear.17 
This is in accordance with findings in our subjects who had 
both the c.G41T variant and other rare and common variants 
of LPL, APOA5, and LMF1.
Our study identified four (15.4%) patients with four rare vari-
ants of APOA5 that were all heterozygous. Three of them were 
novel and all variants were assumed to be disease-causing in 
prediction algorithms. Several rare variants of APOA5 have 
been reported in prior studies, and have been diverse in mul-
tiple ethnicities. The prevalence was 1.1% in a study of patients 
with European ancestry and severe hypertriglyceridemia,18 
2.3% in a Dutch study,12 and 9.2% in a German study.10 The 
prevalence of rare APOA5 variants in our population was rela-
tively higher that of other studies. It is also noteworthy that 
three of four variants in our study were frameshift substitutions 
or insertions. However, it is difficult to tell how much of an ef-
fect these rare variants had on phenotype. A high prevalence 
(53.8%) of the common c.G553T variant of APOA5 was anoth-
er characteristic in our subjects. A previous study showed that 
heterozygous patients of Asian ancestry with this variant have 
2.7 times higher TG levels than controls.9 It is interesting that 
this variant has also been reported in Chinese, Pacific Islander,9 
and Taiwanese populations.3 
We identified three rare variants of LMF1, and two (7.7%) of 
them were predicted to be disease-causing. LMF1 has recently 
been reported to have a role in lipoprotein lipase maturation.19 
To date, although only a few rare variants have been discov-
ered and shown to be relevant to TG levels,16 novel variants of 
LMF1 are being explored. Rare variants were found in 3.4% of 
Spanish patients with severe hypertriglyceridemia. In Dutch 
patients, 9.3% revealed these kinds of variants, although only 
3.5% were linked to the phenotype.12 Taken together, the prev-
alence of rare variants of LMF1 in severe hypertriglyceridemia 
was largely similar between different ethnicities. 
Our study has potential limitations. First, several clinical 
characteristics of the study population selected for re-se-
quencing were different from those of the total population. 
For instance, the mean body mass index and the rate of alcohol 
intake (data not shown) were slightly higher in the study sub-
jects. We cannot completely rule out the fact that these factors 
might have induced secondary elevation of TG. However, we 
tried to minimize these effects by excluding patients with high 
body mass index, uncontrolled diabetes mellitus, or heavy al-
cohol intake. Second, it was difficult to include and examine 
variants in family members of the probands. Because the 
pathogenicity of variants is occasionally clarified by this process, 
we could have obtained more concrete information on the 
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variants if it has been performed. 
In conclusion, we comprehensively analyzed and reported 
the prevalence and characteristics of variants of LPL, APOC2, 
GPIHBP1, APOA5, and LMF1 in Korean patients with very high 
TG. Rare homozygous variants were very uncommon. Ac-
cording to our data, most study subjects may be manifesting 
the combined effects of rare heterozygous variants and com-
mon variants of these genes.
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